These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 27286449

  • 1. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC, Falkenberg N, Hauck SM, Priller M, Braselmann H, Feuchtinger A, Walch A, Schmitt M, Aubele M.
    Oncotarget; 2016 Jul 12; 7(28):44062-44075. PubMed ID: 27286449
    [Abstract] [Full Text] [Related]

  • 2. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    Huber MC, Mall R, Braselmann H, Feuchtinger A, Molatore S, Lindner K, Walch A, Gross E, Schmitt M, Falkenberg N, Aubele M.
    BMC Cancer; 2016 Aug 08; 16():615. PubMed ID: 27502396
    [Abstract] [Full Text] [Related]

  • 3. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A, Mehta SY, Fitzgerald SJ, Woolley AG, Hearn JI, Hurley DG, Ruza I, Algie M, Shelling AN, Braithwaite AW, Print CG.
    Int J Cancer; 2016 Sep 01; 139(5):1157-70. PubMed ID: 27072400
    [Abstract] [Full Text] [Related]

  • 4. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis.
    Huang YT, Lan Q, Lorusso G, Duffey N, Rüegg C.
    Oncotarget; 2017 Feb 07; 8(6):9200-9215. PubMed ID: 27911269
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
    Lai YW, Hsu WJ, Lee WY, Chen CH, Tsai YH, Dai JZ, Yang CC, Lin CW.
    Cells; 2021 Jul 26; 10(8):. PubMed ID: 34440660
    [Abstract] [Full Text] [Related]

  • 6. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.
    Histol Histopathol; 2009 Jul 26; 24(7):869-77. PubMed ID: 19475533
    [Abstract] [Full Text] [Related]

  • 7. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
    Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, Aubele M.
    Oncotarget; 2015 Apr 10; 6(10):8103-14. PubMed ID: 25797271
    [Abstract] [Full Text] [Related]

  • 8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 10; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 9. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B, Xing M, Zeng X, Zhang M, Zheng Q, Wang Z, Peng B, Qu S, Li L, Jin Y, Li H, Yuan H, Zhao Q, Ma C.
    Clin Transl Med; 2024 Jul 10; 14(7):e1753. PubMed ID: 38967349
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.
    Clin Cancer Res; 1995 Oct 10; 1(10):1079-87. PubMed ID: 9815897
    [Abstract] [Full Text] [Related]

  • 11. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan 10; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 12. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
    Reipas KM, Law JH, Couto N, Islam S, Li Y, Li H, Cherkasov A, Jung K, Cheema AS, Jones SJ, Hassell JA, Dunn SE.
    Oncotarget; 2013 Feb 10; 4(2):329-45. PubMed ID: 23593654
    [Abstract] [Full Text] [Related]

  • 13. Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
    Smaradhania N, Rahman S, Ardi Syamsu S, Prihantono P.
    Breast Dis; 2021 Feb 10; 40(S1):S1-S7. PubMed ID: 34057113
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 10; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 15. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL, Seetoo Dq, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ.
    Int J Cancer; 2000 Sep 20; 89(5):431-9. PubMed ID: 11008205
    [Abstract] [Full Text] [Related]

  • 16. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B.
    Oncotarget; 2017 Feb 14; 8(7):11641-11658. PubMed ID: 28036267
    [Abstract] [Full Text] [Related]

  • 17. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Kim HY, Ha Thi HT, Hong S.
    Cancer Lett; 2018 Feb 28; 415():30-39. PubMed ID: 29217458
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y, Dai J, McNamara KM, Bai B, Shi M, Chan MS, Liu M, Sasano H, Wang X, Li X, Liu L, Ma Y, Cao S, Xing Y, Zhao B, Song Y, Wang L.
    BMC Cancer; 2015 Oct 15; 15():699. PubMed ID: 26472563
    [Abstract] [Full Text] [Related]

  • 19. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M, Mourah S, Dosquet C.
    Int J Cancer; 2011 Mar 15; 128(6):1280-92. PubMed ID: 20473943
    [Abstract] [Full Text] [Related]

  • 20. Cyr61 as mediator of Src signaling in triple negative breast cancer cells.
    Sánchez-Bailón MP, Calcabrini A, Mayoral-Varo V, Molinari A, Wagner KU, Losada JP, Ciordia S, Albar JP, Martín-Pérez J.
    Oncotarget; 2015 May 30; 6(15):13520-38. PubMed ID: 25980494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.